1. Home
  2. STEW vs WGS Comparison

STEW vs WGS Comparison

Compare STEW & WGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SRH Total Return Fund Inc.

STEW

SRH Total Return Fund Inc.

HOLD

Current Price

$18.03

Market Cap

1.7B

Sector

Finance

ML Signal

HOLD

Logo GeneDx Holdings Corp.

WGS

GeneDx Holdings Corp.

HOLD

Current Price

$69.81

Market Cap

2.0B

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
STEW
WGS
Founded
N/A
2017
Country
United States
United States
Employees
N/A
1300
Industry
Investment Managers
Retail: Computer Software & Peripheral Equipment
Sector
Finance
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
2.0B
IPO Year
1996
N/A

Fundamental Metrics

Financial Performance
Metric
STEW
WGS
Price
$18.03
$69.81
Analyst Decision
Strong Buy
Analyst Count
0
7
Target Price
N/A
$120.71
AVG Volume (30 Days)
68.9K
653.2K
Earning Date
01-01-0001
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$29.98
Revenue Next Year
N/A
$25.92
P/E Ratio
N/A
$1,251.58
Revenue Growth
N/A
N/A
52 Week Low
$16.55
$55.17
52 Week High
$18.67
$170.87

Technical Indicators

Market Signals
Indicator
STEW
WGS
Relative Strength Index (RSI) 65.27 50.92
Support Level $17.43 $68.55
Resistance Level $18.34 $95.75
Average True Range (ATR) 0.21 4.37
MACD 0.08 1.55
Stochastic Oscillator 82.40 76.72

Price Performance

Historical Comparison
STEW
WGS

About STEW SRH Total Return Fund Inc.

SRH Total Return Fund, Inc. is a non-diversified closed-end management investment company. The company's investment objective is to seek total returns. Its fund utilizes a bottom-up, value-driven investment process to identify securities of good quality businesses trading below estimated intrinsic value. The Funds are available as an actively-managed closed-end fund, an actively managed ETF and a passively-managed ETF.

About WGS GeneDx Holdings Corp.

GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders. The company believes exome and genome testing will become the standard for diagnosing genetic disease, with the potential to transform healthcare from reactive to proactive. It aims to advance precision medicine by offering genetic diagnoses at the earliest moments, driving improved outcomes, and fueling discovery with genomic intelligence. Its operating segment mainly provides pediatric and rare disease diagnostics, focusing on whole exome and genome sequencing and, to a lesser extent, data and information services.

Share on Social Networks: